Background: Adolescents and young adults face unique and complex physical, psychological, and family challenges. Despite improvements in care for chronic kidney disease (CKD) and end-stage kidney disease (ESKD), long-term mortality for children, adolescents, and young adults with CKD remains substantially higher than their healthy counterparts. Summary: In this article, we discuss the complex challenges that adolescent and young adult CKD/ESKD patients face. Adolescents have different CKD etiologies and progress along a course dissimilar to the adult population, but have similar multifarious comorbidities. In the setting of puberty and learning to become self-sufficient, adolescence is a critical time for growth and psychosocial development. Physiological complications of CKD underlie many of the long-term outcomes. CKD-mineral and bone disorder and anemia are particularly challenging given that they are exacerbated by the rapid growth of adolescents. Endocrine imbalances and malnutrition can delay and limit growth. All of these factors, together with family dynamics and socioeconomic status, contribute to the poor long-term outcomes and decreased quality of life (QoL) for these patients and their families. Key Messages: Care for the adolescent CKD/ESKD population is uniquely challenging, but research has identified ways in which we can continue to improve long-term outcomes and QoL for adolescents with CKD/ESKD.

Keywords:
Adolescent, Chronic kidney disease, End-stage kidney disease, Young adult
1.
Ferris ME, Gipson DS, Kimmel PL, Eggers PW: Trends in treatment and outcomes of survival of adolescents initiating end-stage renal disease care in the United States of America. Pediatr Nephrol 2006;21:1020-1026.
2.
Saran R, Li Y, Robinson B, et al: US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015;66(1 suppl 1):Svii, S1-S305.
3.
Harambat J, van Stralen KG, Kim JJ, Tizard EJ: Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012;27:363-373.
4.
Hardy R, Kuh D, Whincup PH, Wadsworth ME: Age at puberty and adult blood pressure and body size in a British birth cohort study. J Hypertens 2006;24:59-66.
5.
Ardissino G, Testa S, Daccò V, Paglialonga F, Viganò S, Felice-Civitillo C, Battaglino F, Bettinelli A, Bordugo A, Cecchetti V, De Pascale S, La Manna A, Li Volti S, Maringhini S, Montini G, Pennesi M, Peratoner L: Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid project. Arch Dis Child 2012;97:885-888.
6.
Schmitt CP, Mehls O: Disorders of bone mineral metabolism in chronic kidney disease; in Geary DE, Schaefer F (eds): Comprehensive Pediatric Nephrology. Mosby Elsevier, 2008.
7.
Wesseling-Perry K, Salusky IB: Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol 2013;33:169-179.
8.
Wesseling K, Bakkaloglu S, Salusky I: Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 2008;23:195-207.
9.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(suppl 113):S1-S130.
10.
National Kidney Foundation: KDOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005;46:S1-S121.
11.
Weber LT, Mehls O: Limitations of dual X-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 2010;25:3-5.
12.
Wesseling-Perry K, Salusky I: Phosphate binders, vitamin D, and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Pediatr Nephrol 2013;28:617-625.
13.
Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K: The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant 2012;27:3063-3071.
14.
Gonzalez E, Schomberg J, Amin N, et al: Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 2010;25:373-375.
15.
Shroff R, Wan M, Gullett A, et al: Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012;7:216-223.
16.
Geary DF, Hodson EM, Craig JC: Interventions for bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 2010;1:CD008327.
17.
Massengill SF, Ferris M: Chronic kidney disease in children and adolescents. Pediatr Rev 2014;35:16-29.
18.
Warady BA, Neu AM, Schaefer F: Optimal care of the infant, child, and adolescent on dialysis: 2014 update. Am J Kidney Dis 2014;64:128-142.
19.
Shroff R, Weaver DJ Jr, Mitsnefes MM: Cardiovascular complications in children with chronic kidney disease. Nat Rev Nephrol 2011;7:642-649.
20.
Sinha R, Marks SD: Pediatric chronic kidney disease; in Wilcox D, Godbole C, Cooper C (eds): Pediatric Urology Book, 2012.
21.
Gerson AC, Butler R, Moxey-Mims M, Wentz A, Shinnar S, Lande MB, Mendley SR, Warady BA, Furth SL, Hooper SR: Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res Rev 2006;12:208-215.
22.
Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, Gipson DS, Lande MB, Shinnar S, Moxey-Mims MM, Warady BA, Furth SL: Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 2010;125:e349-e357.
23.
McKenna AM, Keating LE, Vigneux A, Stevens S, Williams A, Geary DF: Quality of life in children with chronic kidney disease - patient and caregiver assessments. Nephrol Dial Transplant 2006;21:1899-1905.
24.
Kogon AJ, Vander Stoep A, Weiss NS, Smith J, Flynn JT, McCauley E: Depression and its associated factors in pediatric chronic kidney disease. Pediatr Nephrol 2013;28:1855-1861.
25.
Hedayati SS, Yalamanchili V, Finkelstein FO: A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int 2012;81:247-255.
26.
Duarte PS, Miyazaki MC, Blay SL, et al: Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int 2009;76:414-421.
27.
Blydt-Hansen TD, Pierce CB, Cai Y, Samsonov D, Massengill S, Moxey-Mims M, Furth SL: Medication treatment complexity and adherence in children with CKD. CJASN 2014;9:247-254.
28.
Medway M, Tong A, Craig JC, Kim S, Mackie F, McTaggart S, Walker A, Wong G: Parental perspectives on the financial impact of caring for a child with CKD. Am J Kid Dis 2015;65:384-393.
29.
Tsai TC, Liu SI, Tsai JD, Chou LH: Psychosocial effects on caregivers for children on chronic peritoneal dialysis. Kidney Int 2006;70:1983-1987.
30.
Ferris ME, Harward DH, Bickford K, Layton JB, Ferris MT, Hogan SL, Gipson DS, McCoy LP, Hooper SR: A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale. Ren Fail 2012;34:744-753.
31.
Cantú-Quintanilla G, Ferris M, Otero A, Gutiérrez-Almaraz A, Valverde-Rosas S, Velázquez-Jones L, Luque-Coqui M, Cohen S, Medeiros M: Validation of the UNC TRxANSITION Scale™Version 3 among Mexican adolescents with chronic kidney disease. J Pediatr Nurs 2015;30:e71-e81.
32.
Ferris M, Cohen S, Haberman C, Javalkar K, Massengill S, Mahan JD, Kim S, Bickford K, Cantu G, Medeiros M, Phillips A, Ferris MT, Hooper SR: Self-management and transition-readiness assessment: development, reliability, and factor structure of the STARx Questionnaire. J Pediatr Nurs 2015;30:691-699.
33.
Cohen SE, Hooper SR, Javalkar K, Haberman C, Fenton N, Lai H, Mahan JD, Massengill S, Kelly M, Cantú G, Medeiros M, Phillips A, Sawicki G, Wood D, Johnson M, Benton MH, Ferris M: Self-management and transition readiness assessment: concurrent, predictive and discriminant validation of the STARx questionnaire. J Pediatr Nurs 2015;30:668-676.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.